Published in Proteomics Weekly, October 23rd, 2006
Juvaris' vaccine technology will be tested in rodent tumor models to evaluate the impact on leukemia using an antigen-specific immunotherapeutic AML vaccine (JuvaVax). The SBIR grant application was supported by preclinical data...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.